Want to see JP:4552 full AI Analyst Report?

JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

1 Followers

4552 Stock Chart & Stats

¥712.00

-¥21.00(-3.43%)

At close: Jan 08 4:00 PM EST

¥712.00

-¥21.00(-3.43%)

Day’s Range― - ―

52-Week Range¥444.00 - ¥824.00

Previous CloseN/A

Volume326.50K

Average Volume (3M)578.69K

Market Cap

¥63.24B

Enterprise Value¥109.73K

Total Cash (Recent Filing)¥14.01B

Total Debt (Recent Filing)¥53.89B

Price to Earnings (P/E)28.8

Beta0.82

Next Earnings

Jul 30, 2026

EPS Estimate

-11.27

Next Dividend Ex-DateN/A

Dividend Yield3.91%

Share Statistics

EPS (TTM)17.87

Shares Outstanding129,686,310

10 Day Avg. Volume668,090

30 Day Avg. Volume578,686

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)1.48

Price to Sales (P/S)1.72

P/FCF Ratio-5.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥492.00

Price Target Upside-30.90% Downside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)3.27

Revenue Forecast (FY)¥45.59B

Bulls Say, Bears Say

Bulls Say

Specialty/rare-disease FocusJCR's strategic focus on rare-disease biologics concentrates R&D and commercialization where clinical differentiation and reimbursement barriers reduce competition. That niche supports durable pricing power, long product lifecycles and stable institutional demand, aiding revenue and margin resilience over years.

Manufacturing & Contract ServicesIn-house biologics manufacturing and contract production diversify revenue and improve asset utilization. Stable contract manufacturing can generate recurring revenue, deepen customer relationships, and provide a tangible competitive advantage versus pure-play developers that must outsource production.

Revenue Rebound & Gross Profit StrengthA meaningful revenue rebound coupled with consistently strong gross margins indicates core product demand and manufacturing economics remain solid. Sustained gross-profitability gives the company a foundation to restore operating margins if cost structure and cash conversion improve.

Bears Say

Profitability VolatilityLarge year-to-year swings in operating results reduce earnings predictability and complicate long-term planning and R&D prioritization. Volatility raises the risk that temporary gains are reversed, making budgeting, partner deals and investor confidence more difficult to sustain over multiple planning cycles.

Weak Operating & Free Cash FlowPersistent negative operating and free cash flow materially increase funding and execution risk. The company may need external financing for operations or capex, which can dilute stakeholders or raise interest burden, and constrains the ability to fund launches, commercial expansion or R&D internally.

Rising LeverageA meaningful rise in debt reduces financial flexibility and increases refinancing and interest-rate risk. Combined with volatile earnings and negative cash flow, higher leverage magnifies downside risk, can limit strategic options and increases the probability of austerity on R&D or capex during downturns.

JCR Pharmaceuticals Co., Ltd. News

JCR Pharmaceuticals Sets 2026–2027 Timeline to Launch Givinostat for Duchenne Muscular Dystrophy in Japan

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) just unveiled an update. JCR Pharmaceuticals announced a development plan to...

7d ago

4552

JCR Pharmaceuticals Corrects FY2025 Results as Profit Rebounds and Dividend Held Steady

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals has announced partial...

29d ago

4552

JCR Pharmaceuticals Corrects FY2024 Results as Weak Performance Prompts Closer Scrutiny

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals has issued a partial correction...

29d ago

4552

JCR Pharmaceuticals to Grant Restricted Treasury Shares as Long-Term Incentive

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals has approved the disposition of...

29d ago

4552

JCR Deepens Strategic Alliance With Major Shareholder MEDIPAL While Maintaining Independence

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals detailed its relationship...

29d ago

4552

JR-446 Trial Signals Early Rare-Disease Catalyst for Medipal and JCR

Medipal Holdings Corporation ($MEPDF), JCR Pharmaceuticals Co., Ltd. ($JP:4552) announced an update on their ongoing clinical study. The...

1M ago

JCR Pharmaceuticals Corrects Q1 FY2025 Results While Maintaining Full-Year Profit Outlook

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has issued a partial correction...

2M ago

4552

JCR Pharmaceuticals Issues Partial Corrections to FY2024 Consolidated Results Amid Challenging Year

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals Co., Ltd., a global specialty...

2M ago

4552

JCR Pharmaceuticals Corrects Interim Results but Confirms FY2025 Outlook and Dividend Plan

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an announcement. JCR Pharmaceuticals Co., Ltd., a Japan-based specialty...

2M ago

4552

JCR Pharmaceuticals Revises Past Financial Results After Accounting Error Review

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has announced partial corrections to...

2M ago

4552

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?

JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥444.00 and its highest was ¥824.00 in the past 12 months.

What is JCR Pharmaceuticals Co., Ltd.’s market cap?

JCR Pharmaceuticals Co., Ltd.’s market cap is ¥63.24B.

When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?

JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.

How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?

JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.

Is JCR Pharmaceuticals Co., Ltd. overvalued?

According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does JCR Pharmaceuticals Co., Ltd. pay dividends?

JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 3.91%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here

What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?

JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -11.27.

How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?

JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.

What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?

JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.

Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4552

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.

JCR Pharmaceuticals Co., Ltd. (4552) Earnings & Revenues

Historic Earnings Reports

4552 Stock 12 Month Forecast

Average Price Target

¥492.00

▼(-30.90% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"429":"¥429","750":"¥750","509.25":"¥509.3","589.5":"¥589.5","669.75":"¥669.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥540.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":492,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥492.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥430.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[429,509.25,589.5,669.75,750],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,462.46153846153845,468.9230769230769,475.38461538461536,481.84615384615387,488.3076923076923,494.7692307692308,501.2307692307692,507.6923076923077,514.1538461538462,520.6153846153846,527.0769230769231,533.5384615384615,{"y":540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,458.7692307692308,461.53846153846155,464.3076923076923,467.0769230769231,469.84615384615387,472.61538461538464,475.38461538461536,478.15384615384613,480.9230769230769,483.6923076923077,486.46153846153845,489.2307692307692,{"y":492,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,454,452,450,448,446,444,442,440,438,436,434,432,{"y":430,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":493.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580.812,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":614.692,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":623.45,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":588.049,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":749.321,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":700.153,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":595.916,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":649.018,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":594,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >